NEWS DESK

Parse Biosciences Launches 5 Million Cell Evercode WT Penta Kit for Single Cell Sequencing

Parse Biosciences, the leader in high-throughput single cell sequencing, today announced the launch of Evercode™ WT Penta and Penta 384, the first single cell RNA sequencing kits to profile 5 million cells and 384 samples in a single run. Evercode Penta and Penta 384 will begin shipping to customers the week of March 17.

Scaling up single cell experiments—processing millions of cells instead of thousands—has revolutionized the way researchers study development, disease, and cellular heterogeneity. In 2021, Parse set a new benchmark for scalability of single cell experiments with the release of Evercode™ WT Mega, the industry’s highest throughput kit, enabling researchers to push the boundaries of their experimental designs.

With the release of Evercode WT Penta, Parse continues to redefine the limits of single cell research. Penta is the only technology offering fixation and truly unbiased discovery of novel gene expression profiles for five million cells in one run. With its scale, Penta can help researchers identify rare cell types, scale up drug screens, and add more time points or distinct biological samples to their studies and atlasing projects.

“With Evercode Penta, we’re excited to give researchers the power to expand their single cell sequencing studies like never before,” said Charlie Roco, PhD, CTO and Co-founder of Parse Biosciences. “Whether for focused experiments or for large-scale, AI-driven experiments done using Penta or our GigaLab Service, our comprehensive portfolio of solutions ensures that researchers have access to the right tools.”

Parse’s latest innovations also include Mouse BCR and Transgenic Mouse BCR, designed to support antibody discovery and immunology research. Learn more about Evercode Penta at AGBT in Marco Island (February 23-26) or join Parse’s upcoming webinar on March 18.

PR News Desk

PR News Desk

Disclaimer: This press release, supplied by an external third-party provider, is not under the control of this website. The information is provided 'as is' and 'as available,' and has not been edited by this website. Neither this website nor its affiliates can guarantee the accuracy of the content or endorse the opinions expressed in this press release. This press release is intended solely to inform and educate. It does not offer tax, legal, or investment advice or provide any opinion on the suitability, value, or profitability of any specific security, portfolio, or investment strategy. Neither this website nor its affiliates will be held liable for any errors or inaccuracies in the content, nor for any actions you may take based on this information. Using the information in this press release, you agree to do so at your own risk. This website, its parent company, affiliates, directors, officers, employees, agents, advertisers, and content providers, shall not be liable for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages, including but not limited to lost profits, savings, or revenues, whether arising from negligence, tort, contract, or any other legal theory, even if advised of the possibility of such damages or if they could have been reasonably foreseen. Send press releases to press@menews247
Follow Me:

Related Posts